Nevro recently announced its Nevro1 SI Joint Fusion System has been shown to outperform traditional surgical approaches in ...

The Nevro1 System is an FDA 510k-cleared device intended to transfix the SI joint for immediate stability and long-term ...

The Nevro1 sacroiliac joint fusion system was found to be superior compared to posterolateral and lateral approaches, Nevro said Nov. 18.

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the Tenon Medical Third Quarter 2024 ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Using Nevro1 for the treatment of SI joint-related pain allows for the most surface area for fusion, which provides a significantly better opportunity for robust SI joint arthrodesis. Don't Miss our ...

including cervical and lumbar pain due to sacroiliac (SI) dysfunction, and finally discogenic pain. There are currently five randomized trials on the efficacy of RF facet denervation for low back ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud ...

But it can also happen from: Half of people with SI joint pain can trace it back to a specific event, like a car accident or sports injury. Other times, though, there's no obvious reason for the ...

Q3 2024 Earnings Call Transcript November 11, 2024 Nevro Corp. beats earnings expectations. Reported EPS is $-0.51, expectations were $-0.81. Operator: Good afternoon. My name is Krista, and I will be ...

Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, ...